Recipharm, a Swedish pharmaceutical contract development and manufacturing organisation (CDMO), made a deal with Sanofi to buy its contract inhalation drug business and plant in the UK.
The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel (UK) provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market. It also adds additional inhalation commercial drug product manufacturing capabilities, complementing services already offered by Recipharm’s inhalation development facility in the US.
The Holmes Chapel manufacturing facility is located close to Manchester and is one of the leading sites of its type in Europe providing CMO manufacturing services. Several clients are serviced from the facility and a number of products, some of which that are still in their launch phase, are supplied.
As part of the transaction Sanofi have also entered into a long-term supply agreement for the products currently manufactured at the facility. The prime technologies of Holmes Chapel are metered dose inhalers and nasal sprays. The facility houses development areas for dry powder inhalation technologies. The site covers 125,000 m2 and is home to a team of more than 450 specialist employees.
Recipharm is a leading CDMO in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies.